Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence

Detalles Bibliográficos
Autores principales: Abbasi, Haleema Qayyum, Maryyum, Adeena, Khan, Abdul Moiz, Shahnoor, Syeda, Oduoye, Malik O., Wechuli, Polyne N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389599/
https://www.ncbi.nlm.nih.gov/pubmed/37485921
http://dx.doi.org/10.1097/JS9.0000000000000334
_version_ 1785082337364541440
author Abbasi, Haleema Qayyum
Maryyum, Adeena
Khan, Abdul Moiz
Shahnoor, Syeda
Oduoye, Malik O.
Wechuli, Polyne N.
author_facet Abbasi, Haleema Qayyum
Maryyum, Adeena
Khan, Abdul Moiz
Shahnoor, Syeda
Oduoye, Malik O.
Wechuli, Polyne N.
author_sort Abbasi, Haleema Qayyum
collection PubMed
description
format Online
Article
Text
id pubmed-10389599
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-103895992023-08-01 Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence Abbasi, Haleema Qayyum Maryyum, Adeena Khan, Abdul Moiz Shahnoor, Syeda Oduoye, Malik O. Wechuli, Polyne N. Int J Surg Correspondence Lippincott Williams & Wilkins 2023-06-05 /pmc/articles/PMC10389599/ /pubmed/37485921 http://dx.doi.org/10.1097/JS9.0000000000000334 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Correspondence
Abbasi, Haleema Qayyum
Maryyum, Adeena
Khan, Abdul Moiz
Shahnoor, Syeda
Oduoye, Malik O.
Wechuli, Polyne N.
Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
title Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
title_full Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
title_fullStr Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
title_full_unstemmed Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
title_short Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
title_sort advancing precision oncology in breast cancer: the fda approval of elacestrant and guardant360 cdx: a correspondence
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389599/
https://www.ncbi.nlm.nih.gov/pubmed/37485921
http://dx.doi.org/10.1097/JS9.0000000000000334
work_keys_str_mv AT abbasihaleemaqayyum advancingprecisiononcologyinbreastcancerthefdaapprovalofelacestrantandguardant360cdxacorrespondence
AT maryyumadeena advancingprecisiononcologyinbreastcancerthefdaapprovalofelacestrantandguardant360cdxacorrespondence
AT khanabdulmoiz advancingprecisiononcologyinbreastcancerthefdaapprovalofelacestrantandguardant360cdxacorrespondence
AT shahnoorsyeda advancingprecisiononcologyinbreastcancerthefdaapprovalofelacestrantandguardant360cdxacorrespondence
AT oduoyemaliko advancingprecisiononcologyinbreastcancerthefdaapprovalofelacestrantandguardant360cdxacorrespondence
AT wechulipolynen advancingprecisiononcologyinbreastcancerthefdaapprovalofelacestrantandguardant360cdxacorrespondence

Ejemplares similares